% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Teichert:127608,
      author       = {M. Teichert$^*$ and C. Stumpf and N. Booken and M. Wobser
                      and D. Nashan and C. Hallermann and C. Mogler$^*$ and C. S.
                      L. Müller and J. Becker$^*$ and R. K. C. Moritz and M.
                      Andrulis and J. P. Nicolay and S. Goerdt and M. Thomas and
                      C.-D. Klemke and H. Augustin$^*$ and M. Felcht$^*$},
      title        = {{A}ggressive primary cutaneous {B}-cell lymphomas show
                      increased {A}ngiopoietin-2-induced angiogenesis.},
      journal      = {Experimental dermatology},
      volume       = {24},
      number       = {6},
      issn         = {0906-6705},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2017-03631},
      pages        = {424 - 429},
      year         = {2015},
      abstract     = {Primary cutaneous large B-cell lymphomas, leg type
                      (PCLBCL/LT) are primary cutaneous B-cell lymphoma (PCBCL)
                      with an intermediate prognosis. Therefore,
                      antracycline-based polychemotherapy combined with rituximab
                      has been recommended as first-line treatment. Yet, despite
                      this regimen, the 5-year survival rate remains $50-66\%$
                      only. Angiogenesis, the formation of a vascular network, is
                      essential for the pathogenesis of nodal lymphomas. So far,
                      no study has analysed angiogenesis and its key factors in
                      PCLBCL/LT. The present study was aimed at characterizing
                      angiogenesis in PCLBCL/LT to identify the angiogenic
                      molecules as potential therapeutic targets. The
                      intra-tumoral microvessel density (MVD) was assessed by
                      immunohistochemical studies of CD20 and CD31. The MVD was
                      higher in PCLBCL/LT compared with indolent PCBCL. Analyses
                      of open-source microarray data showed correlation between
                      the angiogenic molecule angiopoietin-2 (Ang-2) and
                      pan-endothelial cell markers. ELISA studies determined a
                      shift between Ang-2 and Ang-1 towards Ang-2 in the
                      peripheral blood of PCLBCL/LT patients. Immunofluorescence
                      costainings against the Ang receptor Tie2/angiogenic
                      integrins/CD34 revealed that the vasculature in both
                      aggressive and indolent PCBCL tumors harbours an endothelial
                      cell subpopulation with reduced expression of Tie2. In
                      contrast, the alternative Ang-2 binding partners, angiogenic
                      integrins, are strongly expressed in PCBCL. In line with
                      these findings, downstream targets of Ang-2-integrin
                      signalling, that is phosphorylation of focal adhesion kinase
                      at Tyr397, and sprouting angiogenesis are enhanced in
                      PCLBCL/LT. Our data present Ang-2 as a promising therapeutic
                      target and anti-angiogenic therapy as a new line in
                      treatment of PCLBCL/LT as a hitherto intractable disease.},
      keywords     = {ANGPT2 protein, human (NLM Chemicals) / Angiopoietin-2 (NLM
                      Chemicals) / Integrins (NLM Chemicals) / Focal Adhesion
                      Protein-Tyrosine Kinases (NLM Chemicals)},
      cin          = {A190 / L401 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)A190-20160331 / I:(DE-He78)L401-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {311 - Signalling pathways, cell and tumor biology
                      (POF3-311)},
      pid          = {G:(DE-HGF)POF3-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25776770},
      doi          = {10.1111/exd.12688},
      url          = {https://inrepo02.dkfz.de/record/127608},
}